Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils

Experimental Hematology

Volumn 35, Issue 1, 2007, Pages 108-116

  Krauth, Maria Theresa ^a   Böhm, Alexandra ^a   Agis, Hermine ^a   Sonneck, Karoline ^a   Samorapoompichit, Puchit ^a   Florian, Stefan ^a   Sotlar, Karl ^b   Valent, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GEMTUZUMAB OZOGAMICIN; HISTAMINE; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 3; MESSENGER RNA; STEM CELL FACTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; BASOPHIL; CELL COUNT; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; FEMALE; GROWTH INHIBITION; HISTAMINE RELEASE; HUMAN; HUMAN CELL; INCUBATION TIME; MALE; MAST CELL; MEDIATOR RELEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; STEM CELL; TUMOR CELL; UMBILICAL CORD BLOOD; UPREGULATION;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; APOPTOSIS; BASOPHILS; BLOOD CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; FETAL BLOOD; HISTAMINE; HUMANS; MAST CELLS; STEM CELLS;

EID: 33845782440     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2006.09.008     Document Type: Article

References (37)

1. Bernstein I.D. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia 14 (2000) 474-475
2. Giles F.J. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia. Expert Rev Anticancer Ther 2 (2002) 630-640
3. Bernstein I.D. CD33 as target for selective ablation of acute myeloid leukemia. Clin Lymphoma 2 (2002) 9-11
4. Giles F., Estey E., and O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 98 (2003) 2095-2104
5. Sperr W.R., Florian S., Hauswirth A.W., and Valent P. CD33 as a target of therapy in acute myeloid leukemia: current status and future perspectives. Leuk Lymphoma 46 (2005) 1115-1120
6. Sievers E.L., Appelbaum F.R., Spielberger R.T., et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93 (1999) 3678-3684
7. Bross P.F., Beitz J., Chen G., et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7 (2001) 1490-1496
8. ® Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19 (2001) 3244-3254
9. Sievers E.L. Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg). Blood Cells Mol Dis 31 (2003) 7-10
10. Roboz G.J., Knovich M.A., Bayer R.L., et al. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. Leuk Lymphoma 43 (2002) 1951-1955
11. Larson R.A., Boogaerts M., Estey E., et al. Mylotarg Study Group. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 16 (2002) 1627-1636
12. Giles F.J., Cortes J.E., Halliburton T.A., et al. Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions. Ann Pharmacother 37 (2003) 1182-1185
13. Valent P., Ashman L.K., Hinterberger W., et al. Mast cell typing: demonstration of a distinct hemopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood 73 (1989) 1778-1785
14. Valent P., Majdic O., Maurer D., et al. Further characterization of surface membrane structures expressed on human basophils and mast cells. Int Arch Allergy Appl Immunol 91 (1990) 198-203
15. Valent P., and Bettelheim P. Cell surface structures on human basophils and mast cells: biochemical and functional characterization. Adv Immunol 52 (1992) 333-423
16. van Der Velden V.H., te Marvelde J.G., Hoogeveen P.G., et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97 (2001) 3197-3204
17. Butterfield J.H., Weiler D., Dewald G., and Gleich G.J. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 12 (1988) 345-355
18. Sillaber C., Strobl H., Bevec D., et al. IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. J Immunol 147 (1991) 4224-4428
19. Kishi K. A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors. Leuk Res 9 (1985) 381-390
20. Van Cruchten S., and Van Den Broeck W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol 31 (2002) 214-223
21. Sotlar K., Horny H.P., Simonitsch I., et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 28 (2004) 1319-1325
22. Hauswirth A.W., Natter S., Ghannadan M., et al. Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J Allergy Clin Immunol 110 (2002) 102-109
23. Hauswirth A.W., Florian S., Schernthaner G.H., et al. Expression of cell surface antigens on mast cells: mast cell phenotyping. Methods Mol Biol 315 (2006) 77-90
24. Bühring H.J., Simmons P.J., Pudney M., et al. The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors. Blood 94 (1999) 2343-2356
25. Schernthaner G.H., Hauswirth A.W., Baghestanian M., et al. Detection of differentiation- and activation-linked cell surface antigens on cultured mast cell progenitors. Allergy 60 (2005) 1248-1255
26. Valent P., Spanblochl E., Sperr W.R., et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood 80 (1992) 2237-2245
27. Saito H., Ebisawa M., Sakaguchi N., et al. Characterization of cord-blood-derived human mast cells cultured in the presence of Steel factor and interleukin-6. Int Arch Allergy Immunol 107 (1995) 63-65
28. Valent P., Schmidt G., Besemer J., et al. Interleukin-3 is a differentiation factor for human basophils. Blood 73 (1989) 1763-1769
29. Valent P., Besemer J., Muhm M., et al. Interleukin 3 activates human blood basophils via high-affinity binding sites. Proc Natl Acad Sci U S A 86 (1989) 5542-5546
30. Krauth M.T., Majlesi Y., Sonneck K., et al. Effects of various statins on cytokine-dependent growth and IgE-dependent release of histamine in human mast cells. Allergy 61 (2006) 281-288
31. Escribano L., Orfao A., Diaz-Agustin B., et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 91 (1998) 2731-2736
32. Escribano L., Diaz-Agustin B., Bellas C., et al. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res 25 (2001) 563-570
33. Griffin J.D., Linch D., Sabbath K., Larcom P., and Schlossman S.F. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 8 (1984) 521-534
34. Terstappen L.W., Huang S., Safford M., Lansdorp P.M., and Loken M.R. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells. Blood 77 (1991) 1218-1227
35. Taussig D.C., Pearce D.J., Simpson C., et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 106 (2005) 4086-4092
36. Florian S., Sonneck K., Hauswirth A.W., et al. Detection of molecular targets on the surface of CD34+/CD38- stem cells in various myeloid malignancies. Leuk Lymphoma 47 (2006) 207-222
37. Linenberger M.L. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 19 (2005) 176-182